Postoperative nonspecific immunotherapy in primary bronchogenic carcinoma

A postoperative active nonspecific immunotherapy has been conducted in 54 patients operated on for primary bronchogenic carcinoma. The immunopotentiator used is an original product prepared from a transformed strain of a saprophytic mycobacterium: M. smegmatis ATCC 607. The patients treated show an increase in postoperative survival rates of 60% at 1 year and 50% at 2 years, with regard to the survival rates of a control group and 21 surgical series available totaling over 20,000 patients. This important increase in the survival rates is accompanied by an appreciable improvement in patient comfort.